Laura Stoppel - 24 Jun 2025 Form 4 Insider Report for Artiva Biotherapeutics, Inc. (ARTV)

Reporting relationship: Director
Issuer ticker: ARTV
Reported as of: 24 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Jun 2025, 16:30:15 UTC
Prior SEC filing: 05 Jun 2025
Next SEC filing: 05 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Neha Krishnamohan, Attorney-in-Fact

Key filing fact

Laura Stoppel filed Form 4 for Artiva Biotherapeutics, Inc. (ARTV) on 26 Jun 2025.

Key facts

This page summarizes Laura Stoppel's Form 4 filing for Artiva Biotherapeutics, Inc. (ARTV).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 26 Jun 2025, 16:30.

Change

Previous filing in this sequence was filed on 05 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001865119 Primary reporting owner

Stoppel Laura

Relationship: Director
Address: C/O ARTIVA BIOTHERAPEUTICS, INC., 5505 MOREHOUSE DRIVE, SUITE 100, SAN DIEGO
Signature: /s/ Neha Krishnamohan, Attorney-in-Fact
Signature date: 26 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ARTV transaction Derivative

Director Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +13,750
Change %
Price: $0.000000
Shares after: 13,750
Date: 24 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,750
Exercise price: $1.61
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares subject to the option will vest in full on the earlier of June 24, 2026, or the date of the Issuer's 2026 annual stockholder meeting.

Footnote F2

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the R.A. Capital Healthcare Fund, L.P. (the "Fund"), the R.A. Capital Nexus Fund, L.P. (the "Nexus Fund"), the RA Capital Nexus Fund III, L.P. (the "Nexus Fund III") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.